Lyophilised Oxalobacter formigenes - OxThera AB

Drug Profile

Lyophilised Oxalobacter formigenes - OxThera AB

Alternative Names: IxOC 3; Lyophylised Oxalobacter formigenes; OC 3; OC5; Oxabact; Oxalobacter formigenes product - OxThera AB

Latest Information Update: 30 Nov 2016

Price : $50

At a glance

  • Originator Ixion Biotechnology
  • Developer OxThera
  • Class Bacteria; Probiotics
  • Mechanism of Action Bacteria replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Primary hyperoxaluria; Short bowel syndrome
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No

Highest Development Phases

  • Phase II/III Primary hyperoxaluria
  • Clinical Phase Unknown Short bowel syndrome

Most Recent Events

  • 29 Nov 2016 OxThera plans a phase III trial for Primary hyperoxaluria in USA and European union
  • 18 Jun 2015 Lyophilised Oxalobacter formigenes is still in phase II/III development for Primary hyperoxaluria in France, Germany, Netherlands, USA and United Kingdom
  • 01 Jan 2015 OxThera completes a phase I/II trial in Primary hyperoxaluria in Germany, France and United Kingdom (NCT02012985)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top